Dysfibrinogenemia
| Dysfibrinogenemia | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Abnormal blood clotting, bleeding, thrombosis |
| Complications | Hemorrhage, thromboembolism |
| Onset | |
| Duration | |
| Types | |
| Causes | Genetic mutation in the fibrinogen gene |
| Risks | Family history of the condition |
| Diagnosis | Coagulation test, genetic testing |
| Differential diagnosis | Afibrinogenemia, hypofibrinogenemia |
| Prevention | |
| Treatment | Anticoagulants, fibrinogen concentrate |
| Medication | |
| Prognosis | Variable, depending on severity |
| Frequency | Rare |
| Deaths | |
Dysfibrinogenemia is a rare genetic disorder that affects the blood clotting process. It is characterized by the production of abnormal fibrinogen, a protein that is essential for blood clotting. This condition can lead to either excessive or insufficient blood clotting.
Causes[edit]
Dysfibrinogenemia is caused by mutations in the FGA, FGB, or FGG genes. These genes provide instructions for making the three different chains of the fibrinogen protein. Mutations in any of these genes can result in the production of abnormal fibrinogen.
Symptoms[edit]
The symptoms of dysfibrinogenemia can vary widely, even among members of the same family. Some individuals with this condition do not have any symptoms, while others may experience excessive bleeding or abnormal blood clotting. The most common symptoms include nosebleeds, bruising, menorrhagia (heavy menstrual bleeding), and postpartum hemorrhage (heavy bleeding after childbirth).
Diagnosis[edit]
Diagnosis of dysfibrinogenemia is based on laboratory tests that measure the amount and function of fibrinogen in the blood. Genetic testing can also be used to identify mutations in the FGA, FGB, or FGG genes.
Treatment[edit]
Treatment for dysfibrinogenemia is aimed at managing the symptoms and preventing complications. This may include medications to control bleeding or prevent blood clots, and in severe cases, fibrinogen replacement therapy.
See also[edit]
References[edit]
<references />
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
